Tempus is a healthcare technology company focused on AI-enabled precision medicine. It builds products for providers, life sciences, and patients to support treatment decisions, trial matching, and data-driven research.
Tempus AI signed an agreement to provide precision medicine technology to the University of Southern California. USC will gain access to molecular diagnostics, genomic profiling, clinical trial matching and AI tools.
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Generative AI processed complex medical datasets faster than traditional teams in a preterm birth study, while the healthcare market for the technology reached US$2.92 billion in 2024. The market is projected to grow to US$30.68 billion by 2033 as adoption expands in clinical workflows, imaging, drug discovery and precision medicine.
The global AI in clinical trials market is expected to grow from $2.09 billion currently to $18.62 billion by 2040, driven by enhanced patient recruitment, optimized trial designs, and automation that reduces time and costs in drug development.
Tempus AI and Merck announced an expanded multi-year collaboration to accelerate discovery and development of precision medicine biomarkers using AI and multimodal datasets, focusing on oncology and potentially broader therapeutic areas.
Tempus AI partners with Median Technologies to integrate FDA-cleared eyonis LCS lung cancer screening software into its Pixel platform, marking the first US distribution agreement for the diagnostic tool.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07250646 |
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07211178 |
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies |
RECRUITING | |
| NCT07154823 |
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies |
RECRUITING | |
| NCT06997458 |
Liquid BiOpsy, Lung and Colon Cancer in AndaluciA |
ENROLLING_BY_INVITATION | |
| NCT06911632 |
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension |
RECRUITING | NA |
| NCT06207032 |
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology |
RECRUITING | |
| NCT06163534 |
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) |
RECRUITING | |
| NCT06126003 |
Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer. |
TERMINATED | |
| NCT06099665 |
Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform |
COMPLETED | NA |
| NCT06051695 |
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression |
RECRUITING | PHASE1/PHASE2 |
